Pharmacological interventions targeting oxidative stress have shown efficacy, with vitamin E demonstrating promising results in clinical trials.[21] Furthermore, the sirtuin family of proteins (SIRT1–SIRT7) has emerged as a potential therapeutic target for DC. This evidence concerns the gene SIRT1 and dyskeratosis congenita.